CN102210799B - Medicament for treating peripheral vascular disease - Google Patents
Medicament for treating peripheral vascular disease Download PDFInfo
- Publication number
- CN102210799B CN102210799B CN2011101539345A CN201110153934A CN102210799B CN 102210799 B CN102210799 B CN 102210799B CN 2011101539345 A CN2011101539345 A CN 2011101539345A CN 201110153934 A CN201110153934 A CN 201110153934A CN 102210799 B CN102210799 B CN 102210799B
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- kilograms
- fructus
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicament for treating peripheral vascular disease, characterized by comprising the following traditional Chinese medicinal raw materials in parts by weight for preparing active components of the medicament: 4-8 parts of Chinese starjasmine stem, 4-8 parts of loofah sponge, 2-4 parts of safflower, 3-4 parts of salvia root, 2-3 parts of panax pseudoginseng, 2-4 parts of dogwood, 4-8 parts of Chinese yam, 4-8 parts of tuckahoe, 4-8 parts of dried rehmannia root, 2-4 parts of tree peony bark, 2-4 parts of oriental waterplantain rhizome and 2-3 parts of ricepaperplant pith. All the traditional Chinese medicines are synergic and complementary in actions to play the efficacies of removing obstruction in channels and promoting blood circulation, dispersing blood stasis and alleviating pain, nourishing the kidney and strengthening the spleen, and excreting dampness and promoting the subsidence of swelling. The medicament has good curative effects on treating the peripheral vascular diseases such as thromboangitis obliterans, phlebothrombosis of leg, diabetic peripheral neuropathy, Raynaud's disease, multiple peripheral neuritis and the like.
Description
Technical field
The present invention relates to a kind of medicine of treating peripheral vascular disease.
Background technology
Peripheral angiopathy is " necrosis " or " arthralgia due to stagnation of blood " category in motherland's medical literature.Comprise thromboangiitis obliterans, lower limb vein thrombus, diabetic peripheral neuropathy, Raynaud disease and peripheral polyneuritis etc.
Thromboangiitis obliterans belongs to the category of " necrosis ", and " necrosis " be excited and deficiency of liver-blood mainly due to internal injury, strain excessively, consumption is hindered essence and blood and deficiency of the kidney, then the four stages in the course of an epidemic febrile disease operation is uncomfortable for insufficiency of primordial QI; Eating and drinking without temperance usually, taste are injured, and hypoactivity of spleen-YANG then can not loose essence and blood vessels gradually become QI and blood two to lose; Be added with diseases caused by exogenous pathogenic factor and paddle, receive under the cold-damp, stimulations such as wound and smoking with severe cold, thus deficiency of the liver and kindey, the cold-damp cohesion, stasis of blood resistance meridians, the numbness plug is obstructed, and QI-blood circulation does not freely form.Easy the sending out of the heresy of cold-damp is the transient cause of primary disease, and immanent cause is deficiency of the liver and kindey, and healthy energy is weak, can not resist due to the exopathogen, and cold-damp is the heresy of haze, the easiest yang-energy of hurting sb.'s feelings, and blood gets Wen Zehang, and meeting trembles with fear then coagulates cold blood stasis, meridians blocking barrier, stagnation of QI and blood may bring about pain.Liver blood is not supported then numb.Deficiency of kidney-QI then lower limb is aching and limp unable.Toe (finger) is four ends of human body, be prone to be invaded by cold-damp, insufficiency of kidney-YANG, yang-energy can not fluent four ends then extremity are not warm.When the strongly fragrant heat-transformation of a specified duration of cold-damp, hyperactivity of heat bringing about rottenness of muscle then forms ulcer, gangrene.Liver governing tendons, kidney governing bones, so the primary disease later stage might damage muscles and bones, the characteristics of toe or dactylolysis.If because of excessive noxious heat, pain is insomnia all night, so that cloudy liquid consumption wound, the card of impairment of YIN often occurs.Phase after sick, though toe (finger) bone comes off, pain relief because pus is dripping more than, is not closed up for a long time, so that deficiency of both QI and blood, so can occur the symptom of QI and blood deficiency again.
Deep venous thrombosis of lower limbs also belongs to the disease of " necrosis ", is because blood stasis is stagnated, and blocks venation, the nutrient blood backflow obstruction, and water Tianjin is excessive, gathers and is wet, symptoms such as limb swelling pain occur suffering from, and stasis of blood resistance is that pathological change is basic.Primary disease is a process that constantly changes, and occurs damp and hot symptom of accumulateing resistance in early days, but along with the development of the treatment and the state of an illness, also can be converted into wet resistance of blood stasis or cold-damp blood stasis type, and the latter again can be because of stasis of blood heat-transformation of a specified duration, or is converted into pattern of syndrome such as deficiency of the liver and kindey or deficiency of spleen-YANG and kidneyYANG.Face finding in the card, or be earlier with heat, or with cold be main, or attach most importance to wet, or with void for very, but be accompanied by the pathogenesis of " stasis of blood " all the time.
Diabetic peripheral neuropathy is common complication in the diabetes, and because of the scarcity of suffering from a deficiency of the kidney causes imbalance of YIN and YANG, deficiency of kidney yin person then asthenic fire is grown thickly, and has both gone up the lung spleen that burns, and impairment of body fluid consumption liquid causes Tianjin and do not carry blood; Because of deficiency-heat decocts nutrient blood, hyperamization liquid concentrates, and is popular not smooth again.The insufficiency of kidney-YANG person then is difficult biochemistry, and neither cloth body fluid can not be agitated QI and blood again, so that the arteries and veins cold coagulation is stagnant, and blood flow is slow.Oligospermia has destroyed " YIN and YANG in a relative equilibrium " state normally it is thus clear that suffer from a deficiency of the kidney, and all can cause thrombosis, blood-stasis internal-depression, and venation is lost and is supported.Like belonging to suffer from a deficiency of the kidney " arthralgia due to stagnation of blood ".
Raynaud disease, modern medicine think that it is a kind of peripheral vascular disease due to the autonomic nervous dysfunction, and differential diagnosis in tcm is that the four stages in the course of an epidemic febrile disease is not enough, feel exopathogen again or feelings will is hindered, yang-energy numbness plug, and blood is capable not smooth, genus " arthralgia due to stagnation of blood " category." golden your outline. an arthralgia due to stagnation of blood asthenia piece of writing " cloud: " arthralgia due to stagnation of blood, faintness in both YIN and YANG, feeble pulse at GUAN portion, CHI-pulse being slightly tense, exterior symptoms general numbness and hypoesthesia, symptoms similar to the migratory arthralgia.”
Peripheral polyneuritis is controlled like belonging to the traditional Chinese medical science " arthralgia due to stagnation of blood " opinion.Its pathogeny is that YANG QI deficiency is felt the cold-evil again, so that the cold coagulation stasis owing to plain body blood deficiency, and QI-blood circulation is unfavorable, can not replenishing vital QI with drugs of warm nature four ends.
The generation of " necrosis " or " arthralgia due to stagnation of blood " in a word, because inside and outside composite factor causes the imbalance between the internal organs, meridians generation numbness plug, QI-blood circulation is upset, and is the ultimate principle of morbidity.
Therefore treatment " necrosis " or " arthralgia due to stagnation of blood " should be grasped flexibly, dialectically combines with differential diagnosis of diseases, takes the circumstances into consideration to increase and decrease medication, can medicine demonstrate,proves and is in step with.
The medicine that is used at present to treat peripheral vascular disease clinically has MAILUONING ZHUSHEYE, beniol capsule; Blood circulation and channel invigorating capsule, Radix Ilicis Pubescentis sheet, venation relax open capsule, thrombus-resisting capsules etc., 200410013747.7,200810146980.0,200910083701.5 etc. of Chinese patent report.Although these medicines have certain curative effect, but still need to seek better medicine.Up to now, also there is not to find the medicine report of relevant treatment peripheral vascular disease of the present invention.The inventor is through research repeatedly for many years, and the repeated validation through clinical trial, has found the medicine that the treatment of better curative effect peripheral vascular disease is arranged finally, thereby has accomplished the present invention.
Summary of the invention
The purpose of this invention is to provide a kind of medicine of treating peripheral vascular disease.
The medicine of treatment peripheral vascular disease of the present invention, its raw material of Chinese medicine of processing effective ingredient is selected Caulis Trachelospermi for use: the detumescence of dispelling wind and removing obstruction in the collateral, removing heat from blood, Retinervus Luffae Fructus: collateral dredging, invigorate blood circulation, dispel the wind, be monarch drug; Select Flos Carthami, Radix Salviae Miltiorrhizae and Radix Notoginseng for use: promoting blood circulation to restore menstrual flow, reducing swelling and alleviating pain are ministerial drug; Select Fructus Corni for use: kidney tonifying marrow facilitating, nourishing the liver arresting seminal emission, Rhizoma Dioscoreae: spleen reinforcing nourishing the stomach, the kidney invigorating arresting seminal emission, Poria: promoting diuresis to eliminate damp pathogen, build the spleen mind calming, be adjuvant drug; Select Radix Rehmanniae for use: clearing away heat and cooling blood, YIN nourishing and the production of body fluid promoting, Cortex Moutan: clearing away heat and cooling blood, blood circulation promoting and blood stasis dispelling, Rhizoma Alismatis and Medulla Tetrapanacis: diuresis, clearing away damp-heat are messenger drug.Act on cooperative compensating between each raw material of Chinese medicine, play altogether that collateral dredging is invigorated blood circulation, the effect of blood-activating analgetic, nourishing kidney spleen invigorating, eliminating dampness by diuresis detumescence.
In order to reach the better healing effect,, take the circumstances into consideration to elect additional member the following raw material of Chinese medicine of respectively organizing according to the demand of disease different stages of development:
Rhizoma Zingiberis: warming spleen and stomach for dispelling cold, recuperating depleted YANG are promoted blood circulation, the dampness expectorant, Fructus Chaenomelis: suppressing the hyperactive liver Shujin, stomach function regulating removing dampness, and two flavors are adjuvant, are used for card and see cold and cool person;
Radix Aconiti Preparata and Radix Aconiti Kusnezoffii Preparata: expelling wind and removing dampness, antalgic, two flavors are adjuvant, increase analgesic effect;
Scolopendra and Scorpio: dispelling wind and removing obstruction in the collateral, removing obstruction for relieving pain, Radix Angelicae Sinensis: enrich blood invigorate blood circulation, menstruction regulating and pain relieving, the Radix Astragali: invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation; Four flavors are as adjuvant; The person that is used for the stagnation of QI-blood, dispelling wind and removing obstruction in the collateral is with pain relieving, and promoting blood circulation to remove blood stasis is with migratory arthralgia; QI invigorating is to promote blood circulation, and spleen reinforcing is with flourish flesh.
The consumption of the drug component of treatment peripheral vascular disease of the present invention is also groped to sum up to draw through the inventor in a large number, and each compositional range has better curative effect.
According to a kind of medicine of treating peripheral vascular disease of the present invention, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part.
According to the medicine of treatment peripheral vascular disease of the present invention, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Rhizoma Zingiberis 1.5-3.0 part, Fructus Chaenomelis 4-6 part.
According to the medicine of treatment peripheral vascular disease of the present invention, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Radix Aconiti Preparata 0.8-1.2 part, Radix Aconiti Kusnezoffii Preparata 0.8-1.2 part.
According to the medicine of treatment peripheral vascular disease of the present invention, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Rhizoma Zingiberis 1.5-3.0 part, Fructus Chaenomelis 4-6 part, Radix Aconiti Preparata 0.8-1.2 part, Radix Aconiti Kusnezoffii Preparata 0.8-1.2 part.
According to the medicine of treatment peripheral vascular disease of the present invention, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-32-3 part, Rhizoma Zingiberis 1.5-3.0 part, Fructus Chaenomelis 4-6 part, Radix Aconiti Preparata 0.8-1.2 part, Radix Aconiti Kusnezoffii Preparata 0.8-1.2 part.
According to the medicine of treatment peripheral vascular disease of the present invention, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Scolopendra 0.5-1.0 part, Scorpio 0.5-1.0 part, Radix Angelicae Sinensis 2-4 part, Radix Astragali 4-8 part.
According to the medicine of treatment peripheral vascular disease of the present invention, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Rhizoma Zingiberis 1.5-3.0 part, Fructus Chaenomelis 4-6 part, Scolopendra 0.5-1.0 part, Scorpio 0.5-1.0 part, Radix Angelicae Sinensis 2-4 part, Radix Astragali 4-8 part.
According to the medicine of treatment peripheral vascular disease of the present invention, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Radix Aconiti Preparata 0.8-1.2 part, Radix Aconiti Kusnezoffii Preparata 0.8-1.2 part, Scolopendra 0.5-1.0 part, Scorpio 0.5-1.0 part, Radix Angelicae Sinensis 2-4 part, Radix Astragali 4-8 part.
According to the medicine of treatment peripheral vascular disease of the present invention, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Rhizoma Zingiberis 1.5-3.0 part, Fructus Chaenomelis 4-6 part, Radix Aconiti Preparata 0.8-1.2 part, Radix Aconiti Kusnezoffii Preparata 0.8-1.2 part, Scolopendra 0.5-1.0 part, Scorpio 0.5-1.0 part, Radix Angelicae Sinensis 2-4 part, Radix Astragali 4-8 part.
Method for preparing according to the medicine of described treatment peripheral vascular disease of the present invention:
Take by weighing following raw material of Chinese medicine by weight ratio: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part;
According to the disease difference take the circumstances into consideration to take by weighing following by weight ratio respectively organize raw material of Chinese medicine:
Rhizoma Zingiberis 1.5-3.0 part, Fructus Chaenomelis 4-6 part;
Radix Aconiti Preparata 0.8-1.2 part, Radix Aconiti Kusnezoffii Preparata 0.8-1.2 part;
Scolopendra 0.5-1.0 part, Scorpio 0.5-1.0 part, Radix Angelicae Sinensis 2-4 part, Radix Astragali 4-8 part.
Above-mentioned raw material of Chinese medicine is pressed its times of weight extracting in water 3 times, add water 2-3 for the first time and doubly measures, soak after 5-12 hour and extracted 1.5 hours; For the second time and add water 1-1.5 for the third time and doubly measure, extracted 1 hour, extract between 98 ℃-102 ℃ of the water temperatures at every turn; Extracting liquid filtering; Merging filtrate, concentrating under reduced pressure become 1-2 doubly to measure, packing; Perhaps filtrate decompression is concentrated and between 55 ℃-65 ℃ heat to survey relative density be the thick paste of 1.35-1.40, process bulky grain, vacuum drying; Be ground into fine powder; Take the circumstances into consideration to add required various conventional adjuvant, be prepared into any peroral dosage form commonly used, like pill, tablet, powder, capsule; Slow-releasing microcapsule agent, microcapsule etc., or be prepared into any enema commonly used, suppository etc.
The specific embodimentKilogram, 3 kilograms on Flos Carthami, 3 kilograms of Radix Salviae Miltiorrhizaes, 2 kilograms of Radix Notoginseng, 3 kilograms of Fructus Corni, 6 kilograms of Rhizoma Dioscoreaes, 6 kilograms in Poria, 6 kilograms of Radix Rehmanniae, 3 kilograms of Cortex Moutans, 3 kilograms of Rhizoma Alismatis, 2 kilograms of Medulla Tetrapanaciss.
Method for preparing: said raw material of Chinese medicine is put into extraction pot according to its consumption, and extracting in water 3 times adds 140 kilograms in water for the first time, soaks after 8 hours; Extracted 1.5 hours, and collected extracting solution, respectively add 70 kilograms in water for the second time, for the third time; Extracted respectively 1 hour, and collected extracting solution, filter; Merging filtrate, concentrating under reduced pressure become 80 kilograms, are distributed into every bag 100 gram.
Embodiment 2:
Raw material and consumption: 6 kilograms of Caulis Trachelospermis, 6 kilograms of Retinervus Luffae Fructuss, 3 kilograms on Flos Carthami, 3 kilograms of Radix Salviae Miltiorrhizaes, 2 kilograms of Radix Notoginseng, 3 kilograms of Fructus Corni, 6 kilograms of Rhizoma Dioscoreaes, 6 kilograms in Poria, 6 kilograms of Radix Rehmanniae, 3 kilograms of Cortex Moutans, 3 kilograms of Rhizoma Alismatis, 2 kilograms of Medulla Tetrapanaciss, 2 kilograms of Rhizoma Zingiberiss, 3 kilograms of Fructus Chaenomeliss.
Method for preparing: with embodiment 1.
Embodiment 3:
Raw material and consumption: 6 kilograms of Caulis Trachelospermis, 6 kilograms of Retinervus Luffae Fructuss, 3 kilograms on Flos Carthami, 3 kilograms of Radix Salviae Miltiorrhizaes, 2 kilograms of Radix Notoginseng, 3 kilograms of Fructus Corni, 6 kilograms of Rhizoma Dioscoreaes, 6 kilograms in Poria, 6 kilograms of Radix Rehmanniae, 3 kilograms of Cortex Moutans, 3 kilograms of Rhizoma Alismatis, 2 kilograms of Medulla Tetrapanaciss, 1 kilogram of Radix Aconiti Preparata, 1 kilogram of Radix Aconiti Kusnezoffii Preparata.
Method for preparing: with embodiment 1.
Embodiment 4:
Raw material and consumption: 6 kilograms of Caulis Trachelospermis, 6 kilograms of Retinervus Luffae Fructuss, 3 kilograms on Flos Carthami, 3 kilograms of Radix Salviae Miltiorrhizaes, 2 kilograms of Radix Notoginseng, 3 kilograms of Fructus Corni, 6 kilograms of Rhizoma Dioscoreaes, 6 kilograms in Poria, 6 kilograms of Radix Rehmanniae, 3 kilograms of Cortex Moutans, 3 kilograms of Rhizoma Alismatis, 2 kilograms of Medulla Tetrapanaciss, 2 kilograms of Rhizoma Zingiberiss, 3 kilograms of Fructus Chaenomeliss, 1 kilogram of Radix Aconiti Preparata, 1 kilogram of Radix Aconiti Kusnezoffii Preparata.
Method for preparing: with embodiment 1.
Embodiment 5:
Raw material and consumption: 6 kilograms of Caulis Trachelospermis, 6 kilograms of Retinervus Luffae Fructuss, 3 kilograms on Flos Carthami, 3 kilograms of Radix Salviae Miltiorrhizaes, 2 kilograms of Radix Notoginseng, 3 kilograms of Fructus Corni, 6 kilograms of Rhizoma Dioscoreaes, 6 kilograms in Poria, 6 kilograms of Radix Rehmanniae, 3 kilograms of Cortex Moutans, 3 kilograms of Rhizoma Alismatis, 2 kilograms of Medulla Tetrapanaciss, 0.7 kilogram of Scolopendra, 0.7 kilogram of Scorpio, 3 kilograms of Radix Angelicae Sinensis, 6 kilograms of the Radixs Astragali.
Method for preparing: with embodiment 1.
Embodiment 6:
Raw material and consumption: 6 kilograms of Caulis Trachelospermis, 6 kilograms of Retinervus Luffae Fructuss, 3 kilograms on Flos Carthami, 3 kilograms of Radix Salviae Miltiorrhizaes, 2 kilograms of Radix Notoginseng, 3 kilograms of Fructus Corni, 6 kilograms of Rhizoma Dioscoreaes, 6 kilograms in Poria, 6 kilograms of Radix Rehmanniae, 3 kilograms of Cortex Moutans, 3 kilograms of Rhizoma Alismatis, 2 kilograms of Medulla Tetrapanaciss, 2 kilograms of Rhizoma Zingiberiss, 3 kilograms of Fructus Chaenomeliss, 0.7 kilogram of Scolopendra, 0.7 kilogram of Scorpio, 3 kilograms of Radix Angelicae Sinensis, 6 kilograms of the Radixs Astragali.
Method for preparing: with embodiment 1.
Embodiment 7:
Raw material and consumption: 6 kilograms of Caulis Trachelospermis, 6 kilograms of Retinervus Luffae Fructuss, 3 kilograms on Flos Carthami, 3 kilograms of Radix Salviae Miltiorrhizaes, 2 kilograms of Radix Notoginseng, 3 kilograms of Fructus Corni, 6 kilograms of Rhizoma Dioscoreaes, 6 kilograms in Poria, 6 kilograms of Radix Rehmanniae, 3 kilograms of Cortex Moutans, 3 kilograms of Rhizoma Alismatis, 2 kilograms of Medulla Tetrapanaciss, 1 kilogram of Radix Aconiti Preparata, 1 kilogram of Radix Aconiti Kusnezoffii Preparata, 0.7 kilogram of Scolopendra, 0.7 kilogram of Scorpio, 3 kilograms of Radix Angelicae Sinensis, 6 kilograms of the Radixs Astragali.
Method for preparing: with embodiment 1.
Embodiment 8:
Raw material and consumption: 6 kilograms of Caulis Trachelospermis, 6 kilograms of Retinervus Luffae Fructuss, 3 kilograms on Flos Carthami, 3 kilograms of Radix Salviae Miltiorrhizaes, 2 kilograms of Radix Notoginseng, 3 kilograms of Fructus Corni, 6 kilograms of Rhizoma Dioscoreaes, 6 kilograms in Poria, 6 kilograms of Radix Rehmanniae, 3 kilograms of Cortex Moutans, 3 kilograms of Rhizoma Alismatis, 2 kilograms of Medulla Tetrapanaciss, 2 kilograms of Rhizoma Zingiberiss, 3 kilograms of Fructus Chaenomeliss, 1 kilogram of Radix Aconiti Preparata, 1 kilogram of Radix Aconiti Kusnezoffii Preparata, 0.7 kilogram of Scolopendra, 0.7 kilogram of Scorpio, 3 kilograms of Radix Angelicae Sinensis, 6 kilograms of the Radixs Astragali.
Method for preparing: with embodiment 1.
Clinical trial data:
One, deep vein thrombosis of lower extremity
1, clinical data
This organizes 80 examples, wherein male 28 examples, women 52 examples; Age 44-65 year; One week of the course of disease is with interior 13 examples, 1 week-1 month person 43 example, person's 24 examples more than 1 month; Pathogenic factor: puerperal 44 example, postoperative 17 examples, wound 14 examples infect 2 examples, 3 examples of infusing.Site of pathological change: left lower extremity person 68 examples, right lower extremity person 9 examples, two lower limb person 3 examples, totally 83 lower limb.Ilium silent partners phlebothrombosis 25 examples, femoral vein thrombosis 41 examples, shank gastrocnemius venous plexus thrombosis 14 examples.
2, diagnostic criteria
Suffer from the swelling of limb concordance, two lower limb same level position Zhou Jing differ＞2cm; Color Doppler, ECT or lower limb phlebography show thrombus obstruction scope and position.
3, criterion of therapeutical effect
Clinical recovery: suffer from limb swelling and disappear, two lower limb week poor＜0.05cm in footpath, the no lower limb distending pain in movable back.Produce effects: suffer from limb swelling and obviously alleviate, 0.5cm＜two lower limb week poor≤1cm in footpath, the slight distending pain of movable back lower limb.Effectively: suffer from limb swelling and alleviate, 1cm＜two lower limb week poor≤2cm in footpath still feels the lower limb distending pain after the activity.Invalid: as to suffer from limb swelling and do not disappear, two lower limb week still poor＞2cm in footpath.
4, therapeutic outcome
23 examples of fully recovering (28.8%), produce effects 44 examples (55%), effective 10 examples (12.5%), invalid 3 examples (3.8%), total effective rate 96.3%.
Two, thromboangiitis obliterans
1, clinical data
This organizes 36 examples, male 28 examples, women 8 examples; Age is at 35-70 between year, average 39.5 years old; The course of disease is the longest 20 years, and is the shortest 23 days, average 5.5 years; Site of pathological change right upper extremity 1 example, right lower extremity 14 examples, left upper extremity 2 examples, left lower extremity 14 examples, two lower limb 5 examples.
2, therapeutic outcome
Cure (pain, numbness, send out cool, etc. symptom disappear basically, wound healing, walking lamely appears for 2 kilometers in walking) 14 examples (38.9%), taking a turn for the better, (rest pain alleviates or disappears basically, and Pi Wen, color of the leather is normal or near normal.Wound healing or major part heal or slight intermittent claudication are arranged) 19 examples (52.8%); Invalid (symptom does not have big variation before and after the treatment) 1 example (2.8%); Worsen (gangrenous ulcer extends to more than the ankle joint, or General Symptoms increases the weight of compelled employing amputation) 2 examples (5.6%).Recur 1 example (2.8%).Total effective rate 91.6%.
Three, diabetic peripheral neuropathy
1, clinical data
This organizes 31 examples, male 19 examples, women 12 examples; Age 37-71 year; The course of disease 28 years; All the case initial stages show as acroparesthesia and dyskinesia, like limbs pain, the numbness of being obstructed, pain, scorching hot, send out cold, stabbing pain, step on cotton pad and feel; Or worm climbs sensory disturbances in various degree such as myrmeciasis, even hyperalgia, and depth sensation obviously goes down; Lower limb, knee, Achilles jerk obviously weaken or disappear, and MNCV slows down, and day light night is heavy; Usually symptoms of lower extremity is more more obvious than upper limbs; It is aching and limp unable that severe patient shows as lower limb, stand, difficulty in walking, even paralysis fully.
2, therapeutic outcome
Cure (symptom, sign disappear) 10 examples (32.2%), (symptom, sign obviously alleviate, and do not influence sleep) 17 examples (54.8%) that take a turn for the better, invalid (no significant change before and after the treatment) 3 examples (9.7%).Total effective rate 90.3%.
Four, Raynaud disease
1, clinical data
This organizes 15 examples, is the women; Age 32-46 year; Course of disease 1-5; Symmetry acra burst is pale during outbreak, sends out coolly, is in a cold sweat; Soon transfer livid purple, numb, acupuncture appearance pain to; After a few hours acra rubescent, warm, as ordinary person, the intermittent phase acra can have pain or tingle burn feeling; Acra atrophoderma, ulcer appear in prolonged and repeated outbreak, refer to that (toe) first changes.
2, therapeutic outcome
Cure (symptom, sign disappear, and follow up a case by regular visits to and do not have recurrence in 1 year) 9 examples (60%), (symptom, sign disappear basically, and following up a case by regular visits to 1 year idol has slight outbreak) 6 examples (40%) total effective rate 100% takes a turn for the better.
Five, peripheral polyneuritis
1, clinical data
This organizes 12 examples, male 4 examples, women 8 examples; Age 36-51 year; The course of disease 5 days-3 months; Two lower limb pathological changes person 6 examples, two lower limb pathological changes person 4 examples, upper and lower extremities is pathological changes person's 2 examples simultaneously.It is numb to show as brothers, pain, hyperesthesia, with night for very, brothers are afraid of cold, and are unable, hyperhidrosis.Be developed to both hands carpal joint and two ankle joint gradually.
2, therapeutic outcome
Cure (half a year is followed up a case by regular visits in symptom, sign complete obiteration, does not have recurrence) 9 examples (75%), (symptom, sign disappear basically, follow up a case by regular visits to half a year, and extremity still have slight paralysis sense) 3 examples (25%) total effective rate 100% takes a turn for the better.
The medicine of treatment peripheral vascular disease of the present invention is all cured cure rate 100% to erythromelalgia 5 examples and cold injury 3 examples.
Therapeutic Method and usage and dosage
All cases all adopt the pharmaceutical preparation of embodiment of the invention 1-8 method preparation, and during for oral administration the use 2 times on the 1st, each 100 grams, promptly 1 bag; 15 days 1 courses of treatment, observe 1-4 the course of treatment.
Claims (8)
1. medicine of treating peripheral vascular disease, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part.
2. the medicine of treatment peripheral vascular disease according to claim 1, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Rhizoma Zingiberis 1.5-3.0 part, Fructus Chaenomelis 4-6 part.
3. the medicine of treatment peripheral vascular disease according to claim 1, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Radix Aconiti Preparata 0.8-1.2 part, Radix Aconiti Kusnezoffii Preparata 0.8-1.2 part.
4. according to the medicine of claim 2 or 3 described treatment peripheral vascular diseases, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Rhizoma Zingiberis 1.5-3.0 part, Fructus Chaenomelis 4-6 part, Radix Aconiti Preparata 0.8-1.2 part, Radix Aconiti Kusnezoffii Preparata 0.8-1.2 part.
5. the medicine of treatment peripheral vascular disease according to claim 1, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Scolopendra 0.5-1.0 part, Scorpio 0.5-1.0 part, Radix Angelicae Sinensis 2-4 part, Radix Astragali 4-8 part.
6. the medicine of claim 2 or 5 described treatment peripheral vascular diseases, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Rhizoma Zingiberis 1.5-3.0 part, Fructus Chaenomelis 4-6 part, Scolopendra 0.5-1.0 part, Scorpio 0.5-1.0 part, Radix Angelicae Sinensis 2-4 part, Radix Astragali 4-8 part.
7. according to the medicine of claim 3 or 5 described treatment peripheral vascular diseases, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Radix Aconiti Preparata 0.8-1.2 part, Radix Aconiti Kusnezoffii Preparata 0.8-1.2 part, Scolopendra 0.5-1.0 part, Scorpio 0.5-1.0 part, Radix Angelicae Sinensis 2-4 part, Radix Astragali 4-8 part.
8. according to the medicine of claim 4 or 5 described treatment peripheral vascular diseases, the raw material of Chinese medicine that it is characterized in that processing effective ingredient is pressed the row weight portion and is: Caulis Trachelospermi 4-8 part, Retinervus Luffae Fructus 4-8 part, Flos Carthami 2-4 part, Radix Salviae Miltiorrhizae 3-4 part, Radix Notoginseng 2-3 part, Fructus Corni 2-4 part, Rhizoma Dioscoreae 4-8 part, Poria 4-8 part, Radix Rehmanniae 4-8 part, Cortex Moutan 2-4 part, Rhizoma Alismatis 2-4 part, Medulla Tetrapanacis 2-3 part, Rhizoma Zingiberis 1.5-3.0 part, Fructus Chaenomelis 4-6 part, Radix Aconiti Preparata 0.8-1.2 part, Radix Aconiti Kusnezoffii Preparata 0.8-1.2 part, Scolopendra 0.5-1.0 part, Scorpio 0.5-1.0 part, Radix Angelicae Sinensis 2-4 part, Radix Astragali 4-8 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101539345A CN102210799B (en) | 2011-06-09 | 2011-06-09 | Medicament for treating peripheral vascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101539345A CN102210799B (en) | 2011-06-09 | 2011-06-09 | Medicament for treating peripheral vascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102210799A CN102210799A (en) | 2011-10-12 |
| CN102210799B true CN102210799B (en) | 2012-08-08 |
Family
ID=44742483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101539345A Expired - Fee Related CN102210799B (en) | 2011-06-09 | 2011-06-09 | Medicament for treating peripheral vascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102210799B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727685A (en) * | 2012-07-08 | 2012-10-17 | 李承平 | Set of tablets for removing stasis and dredging collaterals |
| CN104826055A (en) * | 2015-05-11 | 2015-08-12 | 宋宜德 | Traditional Chinese medicine for treating thrombus |
| CN114159530A (en) * | 2020-09-11 | 2022-03-11 | 鲁南制药集团股份有限公司 | Application of Mailuoshutong preparation in preparation of medicine for treating Raynaud syndrome |
| CN115645483B (en) * | 2022-09-28 | 2023-08-18 | 北京岐黄制药有限公司 | Application of composition in preparation of medicine for treating dry age-related macular degeneration |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1398625A (en) * | 2002-08-01 | 2003-02-26 | 李正武 | Chinese medicine prepn for treating obliterans thromboangitis |
-
2011
- 2011-06-09 CN CN2011101539345A patent/CN102210799B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1398625A (en) * | 2002-08-01 | 2003-02-26 | 李正武 | Chinese medicine prepn for treating obliterans thromboangitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102210799A (en) | 2011-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988750B (en) | TCM (Traditional Chinese medicine) composition for treating diabetes and preparation method thereof | |
| CN102772704B (en) | Medicament for treating geriatric disease | |
| CN103041208A (en) | Chinese herbal preparation for treating climacteric syndrome of women, and preparation method thereof | |
| CN102210799B (en) | Medicament for treating peripheral vascular disease | |
| CN103006842B (en) | Drug for treatment of traditional Chinese medicine chest stuffiness and pains | |
| CN101085306B (en) | Oral administration medicament for treating depression | |
| CN104306540B (en) | A kind of treat Chinese medicine preparation of numb limbs and tense tendons and preparation method thereof after brain tumor surgery | |
| CN102988771A (en) | Chinese medicine composition for treating hypertension and preparation method of Chinese medicine composition | |
| CN103007077B (en) | Chinese medicinal composition for treating climacteric syndrome | |
| CN102908474B (en) | Medicinal liquor for treating neurosis | |
| CN1977899B (en) | Medicine for treating rheumatoid arthritis | |
| CN104324340A (en) | Traditional Chinese medicine preparation for treating calcaneal bone hyperplasia and preparation method of traditional Chinese medicine preparation | |
| CN103330837B (en) | Traditional Chinese medicine composition for curing osteoporosis of menopausal women | |
| CN102614405A (en) | Traditional Chinese medicine decoction for curing limb pain caused by diabetic neuropathy | |
| CN102451340A (en) | Traditional Chinese medicine foot bath prescription for treating gout | |
| CN103028089A (en) | Traditional Chinese medicine composition for treating waist pains of middle-aged and old people | |
| CN102935185A (en) | Pills for treating neurasthenia and preparation method | |
| CN103463397B (en) | Traditional Chinese medicine composition for treating deficiency of kidney-yin | |
| CN104958677A (en) | Traditional Chinese medicine preparation for treating membranous nephropathy and preparation method of traditional Chinese medicine preparation | |
| CN101085330A (en) | Oral administration traditional Chinese medicine composition for treating hyperlipoidemia | |
| CN104800553A (en) | Traditional Chinese medicine composition for treating climacteric insomnia and preparation method of traditional Chinese medicine composition | |
| CN103877226B (en) | Bean curd Monopterus albus (Zuiew) gruel with nourishing liver and kidney effect and preparation method thereof | |
| CN102872420A (en) | Medicine for treating rheumatic arthritis and preparation method thereof | |
| CN101843738A (en) | Chinese medicament for treating diabetic feet | |
| CN101244181A (en) | Plaster for bone paralysis with function of qufengshengshi, blood circulation activating and stasis removing, and removing the obstruction in the channels to relieve pain, and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120808 Termination date: 20150609 |
|
| EXPY | Termination of patent right or utility model |